Ten63 Therapeutics Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
29
- Latest Deal Type
-
Series A
- Investors
-
20
Ten63 Therapeutics General Information
Description
Developer of novel antineoplastic therapeutics designed to create remedial medicines to targets previously believed undruggable. The company's therapeutics are created using algorithms to build proprietary scaffold redesign and hopping technology, combining MOA and chemical design to achieve a more durable response, enabling drug researchers to screen trillions of molecules for resistance prediction and antibody redesign.
Contact Information
Website
www.ten63tx.comCorporate Office
- 701 W Main Street
- 5th Floor, Office 05-101
- Durham, NC 27701
- United States
Corporate Office
- 701 W Main Street
- 5th Floor, Office 05-101
- Durham, NC 27701
- United States
Ten63 Therapeutics Timeline
Ten63 Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC (Series A) | 19-Feb-2026 | Completed | Generating Revenue | |||
| 5. Later Stage VC (Series A) | 10-Jan-2025 | Completed | Generating Revenue | |||
| 4. Later Stage VC (Series A) | 08-Apr-2024 | Completed | Pre-Clinical Trials | |||
| 3. Seed Round | 27-Jan-2021 | Completed | Pre-Clinical Trials | |||
| 2. Seed Round | 03-Feb-2020 | $3M | $3.25M | Completed | Pre-Clinical Trials | |
| 1. Accelerator/Incubator | 01-Jan-2019 | $250K | $250K | Completed | Pre-Clinical Trials |
Ten63 Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | ||||||||
| Seed-4 | ||||||||
| Seed-3 | ||||||||
| Seed-2 | 97,089 | $0.000100 | $2.57 | $2.57 | 1x | $2.57 | 2.26% | |
| Seed-1 | 472,877 | $0.000100 | $5.87 | $5.87 | 1x | $5.87 | 11.03% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Ten63 Therapeutics Comparisons
Industry
Financing
Details
Ten63 Therapeutics Competitors (83)
One of Ten63 Therapeutics’s 83 competitors is Relay Therapeutics, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Relay Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Exo Therapeutics | Venture Capital-Backed | Cambridge, MA | ||||
| InterAx | Venture Capital-Backed | Schlieren, Switzerland | ||||
| Vividion Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Eureka Therapeutics | Venture Capital-Backed | Emeryville, CA |
Ten63 Therapeutics Signals
Ten63 Therapeutics Investors (20)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Black Opal Ventures | Venture Capital | Minority | ||
| Cape Fear BioCapital | Venture Capital | Minority | ||
| Chugai Venture Fund | Corporate Venture Capital | Minority | ||
| Gates Foundation | Not-For-Profit Venture Capital | Minority | ||
| Panorama (Tel Aviv) | Venture Capital | Minority |
Ten63 Therapeutics FAQs
-
When was Ten63 Therapeutics founded?
Ten63 Therapeutics was founded in 2018.
-
Where is Ten63 Therapeutics headquartered?
Ten63 Therapeutics is headquartered in Durham, NC.
-
What is the size of Ten63 Therapeutics?
Ten63 Therapeutics has 29 total employees.
-
What industry is Ten63 Therapeutics in?
Ten63 Therapeutics’s primary industry is Drug Discovery.
-
Is Ten63 Therapeutics a private or public company?
Ten63 Therapeutics is a Private company.
-
What is Ten63 Therapeutics’s current revenue?
The current revenue for Ten63 Therapeutics is .
-
How much funding has Ten63 Therapeutics raised over time?
Ten63 Therapeutics has raised $50.5M.
-
Who are Ten63 Therapeutics’s investors?
Black Opal Ventures, Cape Fear BioCapital, Chugai Venture Fund, Gates Foundation, and Panorama (Tel Aviv) are 5 of 20 investors who have invested in Ten63 Therapeutics.
-
Who are Ten63 Therapeutics’s competitors?
Relay Therapeutics, Exo Therapeutics, InterAx, Vividion Therapeutics, and Eureka Therapeutics are some of the 83 competitors of Ten63 Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process